Skip to main content
. 2018 Sep 18;13(9):e0203216. doi: 10.1371/journal.pone.0203216

Table 1. Patient demographics, treatment and tissue characteristics.

Patient No. MPS phenotype Gender Age @ enrolment Age @ start of ERT Surgery Preop ODI4% DS:CS Ratio
1 I HS M 6.2 4 Revision adenoidectomy for OSA. Previous adenotonsillectomy, 2008 12.7 0.74
2 I HS F 9.5 2 Adenotonsillectomy for OSA 15.3 0.7
3 IIIA M 3.4 - Adenoidectomy for nasal obstruction and glue ear 12.5 -
4 IVA F 4.2 3 Tonsillectomy for OSA. Previous adenoidectomy 2011 9.0 -
5 IVA M 12.2 8 Adenoidectomy for OSA. Previous tonsillectomy 2009 45.4 -
6 IVA M 4.3 2 Tonsillectomy for OSA 12.1 -
7 VI F 2.0 1 Adenotonsillectomy for OSA 15.1 2.5 (PRE ERT)
8 VI M 9.7 9 Adenotonsillectomy for OSA. Late diagnosis. - 1.2
9 Control F 4.3 - Adenoidectomy for nasal obstruction and glue ear - -
10 Control F 2.1 - Adenotonsillectomy for mild OSA 5.1 -
11 Control M 4.9 - Adenotonsillectomy for mild OSA 1.3 -
12 Control M 3.4 - Adenotonsillectomy for mild OSA 12.0 -

ERT, Enzyme replacement therapy; Preop ODI4%. Preoperative sleep study oxygen desaturation index 4%; HS, Hurler-Scheie; OSA, Obstructive sleep apnoea.

ERT is not currently available for MPS III